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Michael R. Bishop,1,2 Edwin P. Alyea, III,2,3 Mitchell S. Cairo,2,4 J. H. Frederik Falkenburg,2,5
Carl H. June,2,6 Nicolaus Kr€oger,2,7 Richard F. Little,2,8 Jeffrey S. Miller,2,9
Steven Z. Pavletic,1,2 David L. Porter,2,6 Stanley R. Riddell,2,10 Koen van Besien,2,11
Alan S. Wayne,2,12 Daniel J. Weisdorf,2,9 Roy S. Wu,2,8 Sergio Giralt2,13The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify,
prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Each of theWorkshop’s 6Working Committees has published individual re-
ports of ongoing basic, translational, and clinical research and recommended areas for future research related
to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each
committee’s recommendations and suggests 3 major initiatives for a coordinated research effort to address
the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for
basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the
collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further
refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse
and recommendations for monitoring of minimal residual disease. These recommendations, in coordination
with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly
and efficiently address the significant problem of relapse after allo-HSCT.
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Table 1. Recommendations from the Committee on the
Biological Considerations of Hematological Relapse following
Allogeneic Stem Cell Transplantation Unrelated to Graft-
versus-Tumor Effects
1. Improve the ability to detect and measure rare events, such as LSCs and
genetic and epigenetic lesions. Samples need to obtained
pretransplantation and at the time of relapse for comparison of events.
2. Obtain malignant cells from patients in longitudinal studies (eg, diagnosis,
pretransplantation relapse, posttransplantation relapse) to study changes
in CSC phenotype and frequency.
3. Conduct longitudinal studies on LSC and whole-cell populations from
patients before and after allo-HSCT relative to the development of
resistant mechanisms (eg, growth factors, cell cycle proteins, cell death
mechanisms, drug efflux mechanisms, signaling pathways) to radiation and
chemotherapy.
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rates have concentrated predominantly on modifying
the conditioning regimen either by adding new agents
or increasing doses of available agents. Although dose
intensification resulted in lower relapse rates, these
attempts were generally counterbalanced by increases
in nonrelapse morbidity and mortality [4-6]. The
demonstration that donor lymphocyte infusion (DLI)
could result in complete remissions in patients with
recurrent chronic myelogenous leukemia (CML) [7,8]
led to the exploration of less-intensive regimens aimed
at reducing treatment-related morbidity and mortality
and allowing older andmore debilitated patients access
to allo-HSCT. These regimens are associated with
higher rates of relapse, however [9,10]. Relapse and
disease progression are the leading causes of
treatment failure for most hematologic malignancies
treated with allo-HSCT [11].
TheNational Cancer Institute’s First International
Workshop on the Biology, Prevention, and Treatment
of Relapse after Allogeneic Hematopoietic Stem Cell
Transplantation was organized to bring together lead-
ing experts in the field to comprehensively review the
current state of the science regarding the biology and
treatment of disease recurrence after allo-HSCT [12].
The Workshop’s organizational structure comprised
6 Working Committees that addressed specific areas
considered essential to the problem of relapse after
allo-HSCT, including (1) the biology of graft-versus-
tumor (GVT) effects, (2) the biology of cancer suscep-
tibility and resistance to treatments other than GVT
effects, (3) epidemiology and statistical analysis of re-
lapse, (4) prevention, (5)monitoring, and (6) treatment.
After approximately 1 year of planning andpreparation,
the Workshop was held on November 2-3, 2009, in
Bethesda, Maryland. It included more than 200 inter-
national participants with expertise both within and
outside the transplantation community. The Working
Committees reviewed the current state of the science
and ongoing basic, translational, and clinical research
related to various aspects of their specific area, and
then provided recommendations and topics for discus-
sion and debate among all of the Workshop partici-
pants.
Over the past several months, reports from all of
the 6 Working Committees have been published in
Biology of Blood and Marrow Transplantation [13-19].
These reports provide an encyclopedic scientific
review of various topics related to relapse after allo-
HSCT; describe ongoing basic, translational and clin-
ical research on this subject; and, most importantly,
identify specific areas for future research.
This article summarizes the most salient points
from the Committees’ reports and provides a frame-
work for a coordinated research effort to address the
problem of relapse. The article is divided into two
parts. The first part provides a succinct summary ofresearch questions and proposals put forward by each
Committee. Although these summaries provide some
background information to place these questions and
proposals in proper perspective, they do not adequately
convey the full complexity and breadth of data on each
topic, and the reader is highly encouraged to refer to
the specific Committee reports. The second part of
the article presents general recommendations for a co-
ordinated effort to address the problem of relapse after
allo-HSCT.COMMITTEE RECOMMENDATIONS
Committee on the Biological Considerations of
Hematological Relapse following Allogeneic
Stem Cell Transplantation Unrelated to Graft-
Versus-Tumor Effects
The Committee identified 3 broad areas that re-
quire further study to improve our understanding of
the intrinsic factors and extrinsic factors unrelated to
GVT effects that permit the persistence of tumor
cells beyond the effects of the conditioning regimen
(Table 1). These areas include genomic and epigenetic
lesions/alterations, cancer stem cells (CSCs), and
mechanisms of therapy resistance.Within each of these
areas, there is a need to study rare cell populations and
genetic and epigenetic events, and then to delineate
downstream biochemical pathways that collectively
will form a biological ‘‘fingerprint’’ of the events that
might predict the potential for disease relapse.
Genomic and epigenetic lesions/alterations
Certain genomic and epigenetic changes are stably
transmitted as cells divide and differentiate [20,21]. We
must improve our ability to detect and measure rare
events, such as leukemic stem cell cells (LSCs) and
genetic and epigenetic lesions. Epigenetic information
on LSCs and total malignant cells must be acquired
and compared with nonmalignant somatic cells.
Samples obtained at the time of relapse also could be
used to identify selective GVT effects. Comparing
preconditioning samples and relapse samples of the
Table 2. Recommendations from the Committee on the
Biology Underlying Recurrence of Malignant Disease following
Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction
1. Prioritize basic and translational studies in the following areas:
a. Mechanisms of trafficking, target recognition, and in vivo expansion of
tumor-specific responses
b. Mechanisms that suppress immune responses systemically or locally
at the site of the tumor
c. In vitro generation, expansion, and engineering of specific immune
cells for adoptive transfer
d. Susceptibility of CSCs to immune attack
e. Induction of effective antitumor immunity with vaccines and/or
inhibition of negative regulatory pathways
2. Development of high-throughput screening for antigens involved in
antitumor responses using genome-wide analysis.
3. Human tissue sampling and correlative studies should be built into all
transplantation trials.
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the results of both forms of resistance selection. The
roles of nucleotide polymorphisms, noncoding genes,
and noncoding RNA in leukemogenesis and in the
longitudinal progression of LSCs and whole-
cell populations requires further exploration, in
combination with whole-genome analysis. Novel
bioinformatics methods could be used to validate or
identify new gene interactions and to identify shared or
common nodes in signaling pathways.
Cancer stem cells
The hypothesis that only a subpopulation of rare
CSCs is responsible for maintenance of a tumor has
been supported by studies of acute myelogenous leu-
kemia (AML) [22]. The CSC hypothesis does not
exclude the possibility that over time, these cells may
undergo changes leading to limited or unlimited
self-renewal capacity. This concept has a significant
impact in the context of allo-HSCT, because it sug-
gests that long-term disease control can be achieved
only through posttransplantation therapies or condi-
tioning regimens that specifically target CSCs. There
is a need to obtain malignant cells from patients in
longitudinal studies (eg, diagnosis, pretransplantation
relapse, posttransplantation relapse), given that stem
cell phenotype and frequency can change in the
same patient during the course of disease progression.
Further advances in this field will require improve-
ments in our ability to identify, enumerate, and expand
CSCs, as well as the development of nonhuman pri-
mate models that can be used to screen potential strat-
egies for predicting therapeutic efficacy, monitoring
of minimal residual disease (MRD), and evaluation
of new therapies.
Mechanisms of therapy resistance
The development of resistance to drugs, radia-
tion, or both by tumor cells arises from selection of
resistant clones that have acquired favorable genetic
or epigenetic alterations that increase the cells’ fit-ness. Growth factors, cell cycle proteins, cell death
mechanisms, drug efflux mechanisms, and signaling
pathways that are affected by radiation or chemother-
apy need to be studied longitudinally in LSCs and
whole-cell populations from patients before and after
allo-HSCT.
The Committee also concluded that we currently
lack the necessary tests, assays, and experimental de-
signs to sufficiently study the foregoing issues. In par-
ticular, there is the need to develop new technologies
to isolate and study these rare biological events. One
of the most glaring deficiencies is the lack of robust
preclinical models for evaluation of agents or regimens
that may be predictive of therapeutic efficacy or ability
to promote resistance. However, given access to cell
samples obtained before and after relapse after allo-
HSCT, it is likely that currently available technologies
could identify critical biomarkers that would permit
the identification of patients at risk for relapse. In
the future, it may be possible to develop tailored or
‘‘personalized’’ conditioning regimens that might mit-
igate the evolution of resistance to allogeneic cellular
procedures.Committee on the Biology Underlying
Recurrence of Malignant Disease following
Allogeneic HSCT: Graft-versus-Tumor/
Leukemia Reaction
Relapse occurs either because the residuals cells
that were not eliminated by the conditioning regimen
evade the immune response provided by the trans-
plantation of donor cells or because the immune re-
sponse cannot be sustained. Immune responses after
allo-HSCT and DLI illustrate the robust potential
of allogeneic T cell, natural killer cell, and/or anti-
body responses to treat patients with hematologic ma-
lignancies. Thus, the central questions are why
certain diseases, particularly CML, respond better
to the adoptive transfer of allogeneic lymphocytes
than other diseases, and why in those diseases that
do initially respond, this response is lost, resulting
in relapse.
Several issues have limited the successful applica-
tion of allogeneic cellular therapy, particularly detri-
mental graft-versus-host disease (GVHD) in patients
experiencing clinically significant antitumor re-
sponses. A major objective of allo-HSCT research
has been to separate GVHD fromGVTwithout incur-
ring a loss of protection against infections [23]. How-
ever, the complexity of the interactions between the
alloimmune response and tumor biology has made
achieving this objective very difficult. The prerequi-
sites for successfully achieving this objective include
identifying relevant target structures and the type of
effector cells required for optimal and specific re-
sponses and gaining a better understanding of the
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essary for tumor elimination [24,25]. There is also the
need to better understand the induction, expansion,
and trafficking of immune responses, which may
allow specific recognition of hematopoietic tissues
from host and nontarget organs of GVHD [26].
Knowledge of the tumor biology limiting the effective-
ness of alloimmune responses to execute a specific an-
titumor effect is essential to increase the likelihood of
success with no or only limited toxicity. These factors
include escape mechanisms of tumor cells to prevent
recognition and elimination by alloimmune responses
and also may include down-regulation of the target
structures to be recognized, suppression of homing
or interaction at the tumor site, or development of sup-
pressive factors preventing the development of im-
mune responses in vivo.
Future initiatives to identify and overcome the
obstacles preventing the successful application of allo-
geneic cellular therapy for the treatment of hemato-
logic malignancies should include studies of T cells,
natural killer cells, and antibody-mediated mecha-
nisms (Table 2). Specific studies that may be per-
formed in either animals and/or man should include
(1) studies to better understand mechanisms of traf-
ficking, target recognition, and in vivo expansion of tu-
mor specific responses; (2) studies of mechanisms that
suppress immune responses systemically or locally at
the tumor site; (3) studies on the in vitro generation,
expansion, and engineering of specific immune cells
for adoptive transfer; (4) studies on the susceptibility
of CSCs to immune attack; (5) studies on the induction
of effective antitumor immunity with vaccines or inhi-
bition of negative regulatory pathways; and (6) high
throughput screening for antigens involved in antitu-
mor responses using genome-wide analysis.
Accomplishing any of these studies will require
major initiatives to provide the framework and infra-
structure for their execution. Specifically, human tis-
sue sampling and correlative studies should be built
into all transplantation trials. Related to this, efforts
and support should be made to utilize and coordinate
existing biorepositories for the collection, storage,
and distribution of these samples. Data from these cor-
relative studies and provision of human samples will fa-
cilitate the translation of basic research into successful
clinical research strategies and will guide the design of
clinical trials. However, this will require sufficient fi-
nancial support for sample collection, storage, and ad-
ministration, as well as supportive collaboration
among institutions and investigators. Additional fund-
ing, possibly through specific directed Requests for
Applications (RFA), Program Project Grants (P01),
or similar funding mechanisms, will be essential to
provide the necessary support. This might be secured
by promoting interactive program grants and utilizing
existing institutional core resources.Committee on the Epidemiology and Natural
History of Relapse following Allogeneic Cell
Transplantation
The epidemiology and natural history of relapse af-
ter allo-HSCT involve certain factors that can be eval-
uated across a variety of diseases and those that are
disease-specific. Factors that affect the incidence of re-
lapse regardless of disease or disease status include
graft manipulation (eg, T cell depleted vs T cell re-
plete), conditioning regimen (myeloablative vs
reduced-intensity), donor source (related vs unrelated,
HLA disparity), and immunosuppression used for
GVHD prevention (agent, dose, duration). After allo-
HSCT, additional factors affect relapse, particularly
the presence or absence of GVHD and the agents
used to treat it. Relapse and survival need to be assessed
in relation to newer agents (eg, tyrosine kinase inhibi-
tors in CML, hypomethylating agents in myelodys-
plastic syndromes), contemporary supportive care,
and comparable patient populations. Several factors
are disease-specific relative to the risk and subsequent
outcome of relapse after allo-HSCT, however. The
difficulty lies in the absence of adequate data on the ep-
idemiology and natural history of many diseases, par-
ticularly the lymphomas, when taking into account
the factors that affect relapse, such as specific histology,
cytogenetics, genetic mutations, disease state, and sen-
sitivity to chemotherapy, all of which have been identi-
fied as affecting relapse incidence and outcome.
As such, epidemiologic studies need to provide data
with details on disease status, previous treatments, bio-
logical markers, and posttransplantation events. Analy-
ses of larger cohorts throughmulticenter collaborations
or registries remain essential to probe questions not
amenable to or impractical in single-center or prospec-
tive studies. Stringent and consistent statisticalmethods
for studying relapse remain an important area of re-
search.The opportunities for improving the prevention
andmanagement of post–allo-HSCTrelapse are appar-
ent, but clinical data to permit the prompt identification
of patients at risk and who would benefit from preemp-
tive therapy are lacking. A better understanding and
monitoring of MRD after allo-HSCT could lead to
novel preemptive treatments of relapse; however, selec-
tion bias necessitates prospective assessment to gauge
the real contribution of any new therapies.
Specific areas are considered of high priority rela-
tive to the epidemiologic study of relapse (Table 3).
First, it is necessary to redefine remission and relapse
in each disease using new methodologies (as further
defined later), as well as MRD thresholds using stan-
dardized morphologic, cytogenetic, flow cytometric,
and molecular techniques. Second, data from such
studies would be used to develop new or modify cur-
rent prognostic scoring systems (eg, the International
Prognostic Index in non-Hodgkin lymphoma) that
Table 3. Recommendations from the Committee on the
Epidemiology and Natural History of Relapse following Allo-
geneic Cell Transplantation
1. Refine remission and relapse definitions in each disease using remission
guidelines and MRD thresholds recommended by the Committee on
Disease-Specific Methods and Strategies for Monitoring Relapse following
Allogeneic Stem Cell Transplantation.
2. Develop new or modify current prognostic scoring systems (eg, the
International Prognostic Index in non-Hodgkin lymphoma) that are
specific for relapse.
3. Develop statistical methods for the study of relapse. These would include
the use of cumulative incidence function with time-dependent covariates.
4. Develop networks of transplantation centers willing to provide extra data
to the various transplantation registries and cooperative groups to define
high-risk subsets of patients in each disease and disease category.
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there is the need to develop statistical methods that
are specific for the study of relapse. These would in-
clude the use of the cumulative incidence function
with time-dependent covariates. Finally, the develop-
ment of networks of transplantation centers willing
to provide extra data to the various transplantation reg-
istries and cooperative groups is highly encouraged to
define high-risk subsets of patients in each disease and
disease category. Again, additional funding will be es-
sential to support the increased workload placed on
such institutions. The value of these networks would
be enhanced if they were to include a central tissue
bank as well.Committee on Prevention of Relapse following
Allogeneic Cell Transplantation for
Hematological Malignancies
There have been several attempts, some ongoing,
to prevent relapse after allo-HSCT, including modi-
fication of the conditioning regimen, modification of
the allograft, preemptive therapy in the peritrans-
plantation period, and maintenance therapy later
posttransplantation [27-29]. However, no one
strategy or combinations of strategies has been
clearly demonstrated to reduce the incidence or the
subsequent outcome of relapse after allo-HSCT.
There are several unique opportunities for investiga-
tion in each of these areas.With regard to conditioning
regimens, the ultimate goal is to achieve a state of
MRD with a decrease (or, at a minimum, with no in-
crease) in nonrelapse mortality. One strategy might in-
volve the selection of conditioning regimens based on
disease and disease state, with higher-risk and aggres-
sive malignancies requiring more intensive condition-
ing regimens. The biggest question that faces the
transplantation community is whether we should aban-
don high-dose conditioning regimens altogether and
focus on developing alternative strategies to achieve
MRD with less toxicity through the use of novel and
targeted agents (eg, histone deacetylase [HDAC] in-
hibitors, hypomethylating agents, proteasome inhibi-
tors, monoclonal antibodies) with pretransplantationsalvage treatment, low-intensity conditioning regi-
mens, and subsequent therapy in the immediate post-
transplantation period. Optimal criteria for agents
used in the pretransplantation and peritransplantation
periods would include the following: (1) no increased
morbidity, (2) either additive or synergistic effects
with the agent(s) with which they are combined, and
(3) either no effect on or an enhancing effect on GVT.
Several new areas related to graft manipulation
need to be tested, including the selective depletion of
the donor graft to eliminate cells most likely to cause
GVHD while maintaining GVL (eg, alloreactive and
na€ıve T cells) and the addition of cells that suppress
GVHD (eg, regulatory T cells, mesenchymal stem
cells). However, before these new approaches can be
tested, several elementary questions remain to be an-
swered, including understanding the critical innate
and adaptive immune cells, the mechanisms involved
in mediating GVHD and GVL, and the optimal graft
composition.
In the posttransplantation period, cellular therapy
could include prophylactic treatment with T cells that
specifically target malignant cells by either selection or
genetic modification (eg, chimeric antigen receptors)
and vaccines, either alone or in combination with den-
dritic cells. Essential questions remain related to the
timing, dose, and frequency of the prophylactic use
of standard DLI.
It is the Committee’s recommendation that future
trials should be disease-specific (Table 4). However,
before initiating such disease-specific trials, additional
disease-specific epidemiologic and biomarker studies
are needed.These include thedevelopment of validated
prognostic scoring systems to identify patients at risk
for relapse in the posttransplantation period. Critical
to this effort is the need to standardize methods that
are clinically significant and reproducible to measure
MRD, assess the predictive value ofMRD, and validate
MRD measures. Ultimately, such measurements also
may serve as surrogate markers for study endpoints,
particularly response, which would enable shorter
follow-up times and allow for more rapid clinical trial
completion and development of subsequent lines of in-
vestigation. Finally, while epidemiologic studies are in
progress for specific diseases, efforts should be placed
on initiating trials in diseases for which measurement
of MRD and biomarkers are relatively well established
and novel agents are available (eg, TKI in Philadelphia
chromosome–positive acute lymphoblastic leukemia
[ALL], bortezomib in multiple myeloma).Committee on Disease-Specific Methods and
Strategies for Monitoring Relapse following
Allogeneic Stem Cell Transplantation
There is clinical evidence indicating that interven-
tion before florid relapse after allo-HSCT through
Table 4. Recommendations from the Committee on Pre-
vention of Relapse following Allogeneic Cell Transplantation
for Hematologic Malignancies
1. Identification of epidemiologic parameters and biomarkers to identify
patients at risk for relapse in the posttransplantation period, to enhance
and validate the measurement of MRD, and to serve as surrogate markers
for study endpoints, particularly response, which would enable shorter
follow-up times and allow for more rapid clinical trial completion and
development of subsequent lines of investigation.
2. Development of disease-specific clinical trials:
a. Trials should be implemented immediately in diseases for which
measurement of MRD and biomarkers are relatively well established
and novel agents are available.
b. Future trials should incorporate alternative strategies to achieve
MRD with less toxicity. This would include use of novel and targeted
agents in the peritransplantation and posttransplantation periods.
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with CML undergoing allo-HSCT [30]. Similarly, it
has been clearly shown that in pediatric patients with
ALL, serial analysis of chimerism and MRD can pre-
dict impending relapse, and that early initiation of im-
munotherapy can prevent relapse in some patients
[31]. However, in the majority of hematologic malig-
nancies for which allo-HSCT is used, the clinical rel-
evance of MRD surveillance and the potential impact
of specific interventional strategies have not yet been
fully elucidated. A wide variety of techniques are avail-
able to monitor residual disease after therapy, includ-
ing in the posttransplantation setting, although
applicability varies by specific disease subtype, and
the predictive value of each method is currently not
well defined for most diseases. Criteria for determin-
ing remission status and relapse and detection of
MRD have been established for a variety of diseases,
and these criteria also could be integrated into the as-
sessment of remission in the posttransplantation pe-
riod. Whether these techniques and criteria are
applicable and have validity in the allo-HSCT setting
has not been clearly determined.
The development of standard techniques to mon-
itor MRD and criteria and definitions to define relapse
and response to treatment specific for allo-HSCT are
essential for the proposed studies by the other Work-
shop Committees related to the natural history and
the epidemiology, prevention, and treatment of re-
lapse. It is with this understanding that the Committee
on Disease-Specific Methods and Strategies for Mon-
itoring Relapse undertook the challenge of developing
disease-specific recommendations for the assessment
and definitions of relapse and response after allo-
HSCT, as well as specifying the disease-specific
monitoring methods needed to make these assess-
ments [18,19]. These recommendations took into
account existing definitions and criteria, practicality,
and reproducibility. It is a specific intent of the
Workshop that these definitions of remission and
relapse be further refined and that methods for
monitoring or MRD be incorporated into all futuretransplantation trials, to provide consistency in
reporting and interpretation of data (Table 5). These
recommendations (Table 6) are made cautiously with
several caveats inmind. First, standardization is critical
to the conduct of multicenter studies needed to assess
the utility of MRD monitoring in the prediction and
possible prevention of overt relapse. Quality control
and standardization are essential to ensure compara-
bility of MRD results between different laboratories.
Second, various new techniques and markers are
emerging, and efforts must be made to incorporate
these techniques as they become available. Third,
these recommendations are not meant to be definitive.
Many of the established definitions of remission and
relapse used to evaluate most hematologic malignan-
cies during upfront therapy lack sufficient sensitivity
for use after allo-HSCT. As such, standardization
and implementation of the different MRDmonitoring
techniques are critically important. These recommen-
dations are meant to serve as a starting point for sys-
tematic use and evaluation among transplantation
studies. Studies to assess the utility of these recom-
mendations in each disease entity are needed. In par-
ticular, the optimal time points for their use and the
predictive value of posttransplantationMRDmonitor-
ing need to be prospectively assessed. Subsequent
studies must then be performed to evaluate the efficacy
of these methods to guide therapeutic interventions
designed to prevent overt relapse. Specifically, critical
objectives for future studies using the proposed
methods and criteria should include the following:
(1) to standardize measurement of molecular markers
for each hematologic malignancy for which allo-
HSCT is used, (2) to determine the optimal frequency
formonitoringMRD and chimerism after allo-HSCT,
(3) to define kinetic changes in MRD and chimerism
that occur after allo-HSCT and establish criteria that
incorporate measurement of these molecular markers
in the definition of response and remission after allo-
HSCT, and (4) to assess the efficacy of interventional
strategies based on changes inMRD and/or chimerism
to prevent clinical relapse.Committee on Treatment of Relapse after
Allogeneic Hematopoietic Stem Cell
Transplantation
The treatment of relapse after allo-HSCT is de-
pendent on many factors, including disease activity,
timewhen the relapse occurred, clinical complications,
presence or absence of immunosuppression and/or
GVHD, previous therapies, donor availability, suscep-
tibility to GVT induction, and several other logistical
and clinical issues. Other than the documented success
of using DLI for relapsed CML, there are remarkably
limited data on the efficacy of DLI and non-DLI ther-
apies in other clinical situations. Furthermore, the
Table 5. Response and Relapse Definitions after Allo-HSCT: Application of Monitoring Methodologies
Disease
Definition of Complete
Remission Definition of Relapse Molecular Markers Cytogenetics Chimerism Imaging Flow Cytometry Other Methods
ALL <5% blasts in
bone marrow
>5% blasts in bone
marrow
TCR and Ig gene rearrangement Chromosome banding
analysis, FISH
PCR or VNTR/STR 4- to 6-color multiparameter
flow cytometry
Applicable All patients All patients 90% of all patients Subgroups All patients Not applicable > 95% of patients
Comment ASO primer: 80%-90% of patients;
Ig VDJ: most patients; BCR-ABL1:
all Philadelphia chromosome‒
positive ALL patients
Not important for MRD
assessment
Gold standard: single-plex PCR
with fluorescent-labeled STR
primers. Important:
product resolution using
capillary electrophoresis
Sensitivity in B-lineage ALL is
limited after HSCT due to
large numbers of
hematogones.
AML/MDS IWG IWG Molecular mutations Chromosome banding
analysis, FISH
PCR or VNTR/STR 4- to 8-color multiparameter
flow cytometry
Applicable All patients All patients Subgroups Subgroups All patients Not applicable All patients
Comment Well established Well established, but
less sensitive
Expansion of MRD marker
panel for posttransplantation
monitoring in AML
(eg, NPM1 mutations) or MDS
(eg, RUNX1/AML1 mutations)*
No standardization for
MRD monitoring,
useful for specific
aberrations*
Well-established lack of
specificity: investigation of
CD34+-specific chimerism*
and standardization
of techniques
Few studies*
CLL IW-CLL/NCI IW-CLL/NCI ASO primer IGH qPCR Chromosome banding
analysis, FISH
PCR or VNTR/STR CT MRD multiparameter
flow cytometry
Applicable All patients All patients  90% Subgroups All patients All patients > 95%
Comment IW-CLL definition of MRD
negativity: MRD <1024
by qPCR or flow.
Predictive for sustained
remission if <1024 at 1 year
post-HSCT; more sensitive
than flow (<1024).
No role in relapse
monitoring.
Complete donor chimerism
usually a prerequisite for
MRD negativity, but not
suitable as MRD marker.
Only to be used in
patients in complete
remission based on
clinical methods or
in clinical trials.
Predictive for sustained
remission if <1024
at 1 year after
allo-HSCT.
CML Hematologic; cytogenetic;
molecular
Hematologic;
cytogenetic;
molecular
BCR-ABL1 reverse-
transcription PCR
Chromosome banding
analysis, FISH
PCR or VNTR/STR 4- to 6-color multiparameter
flow cytometry
Applicable All patients All patients All patients All patients All patients Not applicable Subgroups
Comment qPCR identifies relapse
risk groups.
Not as sensitive as qPCR
for MRD detection.
Only helpful in identifying
aberrant blasts in advanced
phase disease.
Lymphoma Cheson criteria Cheson criteria ASO primer (IgH) for B cell NHL Chromosome banding
analysis, FISH
PCR or VNTR/STR CT/PET 4- to 6-color multiparameter
flow cytometry
Applicable All patients All patients Subgroups Subgroups All patients All patients Subgroups
Comment Well established for
all lymphomas
Well established
for all lymphomas
Bcl-2 for FL; Bcl-1 for 30% of
MCL; clonal TCR
rearrangements for
T cell NHL
t(14;18) for FL; t(11,14)
for MCL
Monitoring PF T cells by PCR
useful in NHL; role not
established in Hodgkin
disease.
Well established in
all lymphomas
Could be helpful for follicular
lymphoma and mantle
cell lymphoma.*
Multiple myeloma EBMT; IMWG EBMT; IMWG ASO primer (IgH) Chromosome banding
analysis, FISH
PCR or VNTR/STR MRI; PET-CT 4- to 8-color multiparameter
flow cytometry
Free light-chain assay
Applicable All patients All patients 40%-80% Subgroups All patients All patients All patients Subgroups
Comment Accepted but less
sensitive.
Accepted but less
sensitive.
Important but not included
in EBMTand IMWG
definition.
May be useful.* Mononuclear cell donor
chimerism not useful.
Lineage-specific donor
chimerism (CD138+ plasma
cells) predicts relapse.*
Not established,
but useful for
extramedullary
disease.*
More sensitive than
EBMT/IMWG in
predicting relapse.*
Proposed by IMWG,
but no valid data
are available.*
Myelofibrosis IWG-MRT IWG-MRT JAK2/MPL Chromosome banding
analysis, FISH
PCR or VNTR/STR MRI Flow cytometry
Applicable All patients All patients Subgroups Subgroups All patients All patients All patients
Comment Not fully applicable. Not fully applicable. High sensitivity and predictive
for relapse.*
Not investigated.* Correlates with molecular
marker, but less specific.*
Correlates with
fibrosis
regression.*
Circulating CD34+ cells
may be useful.*
MDS indicates myelodysplastic syndromes; MRI, magnetic resonance imaging; NCI, National Cancer Institute; NHL, non-Hodgkin lymphoma; PCR, polymerase chain reaction; qPCR, quantitative real-time PCR; STR,
short tandem repeat; TCR, T cell receptor; VNTR, variable number tandem repeat; IWG-MRT, International Working Group for Myelofibrosis Research and Treatment; IMWG, International Myeloma Working
Group; IW-CLL, International Workshop on Chronic Lymphocytic Leukemia; PET, positron emisson tomography; CT, computerized axial tomography.
*Further studies are needed.
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Table 7. Recommendations from the Committee on Treat-
ment of Relapse after Allogeneic Hematopoietic Stem Cell
Transplantation
1. Conduct well-designed international cooperative trials that are disease-
specific to rapidly test and disseminate the best strategies for relapse
treatment after transplantation. Specifically, there is a need for disease-
specific clinical trials in the following areas:
a. In patients eligible to receive DLI, determination of whether there is
a dose-response effect or a minimal threshold dose that must be
achieved before antitumor responses occur;
b. Design and implementation of Phase I and II trials for patients who are
ineligible to receive DLI (eg, active GVHD) or in whom cellular
therapies have been ineffective.
2. All clinical trials designed for the treatment of relapse after allo-HSCT
should contain:
a. Measurement of immunologic effects in addition to disease outcomes;
b. Treatment response criteria using Workshop-suggested methods.
3. Organizations that execute clinical trials for the treatment of relapse after
allo-HSCT should create and maintain databases that deal specifically with
relapse information.
Table 6. Recommendations from theCommittee onDisease-
Specific Methods and Strategies for Monitoring Relapse fol-
lowing Allogeneic Stem Cell Transplantation
1. Specific definitions for posttransplantation remission and relapse using
sensitive methods for monitoring or MRD as proposed by the Committee
should be incorporated into all future transplantation trials to provide
consistency in reporting and interpretation of data.
2. Multicenter studies need to be conducted with specific
posttransplantation definitions for remission and relapse using sensitive
methods for monitoring or MRD for each disease entity to:
a. Assess whether the results obtained with methods are reproducible
across different institutions and laboratories to ensure that results are
comparable.
b. Assess their utility in the prediction of overt relapse.
3. Once the reproducibility and utility of these definitions and methods are
established, subsequent studies should be performed to evaluate the
efficacy of these methods to guide therapeutic interventions designed to
prevent overt relapse. Specifically, future studies should include the
following:
a. Standardized measurement of molecular markers for each
hematologic malignancy for which allo-HSCT is used;
b. Determination of the optimal frequency for monitoring MRD and
chimerism after allo-HSCT;
c. Definition of kinetic changes in MRD and chimerism that occur after
allo-HSCT and modification of criteria for remission and relapse,
followed by incorporation of these measures in the definitions of
response and remission after allo-HSCT;
d. Assessment of the efficacy of interventional strategies–based changes
in MRD and/or chimerism to prevent clinical relapse.
4. As new techniques and markers emerge, every effort must be made to
incorporate these techniques and markers into proposed definitions and
methods as they become available.
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rapidly after transplantation is likely very different
from that of disease that relapses later after transplan-
tation. Thus, treatment options are likely to vary be-
tween these different patient groups. As such, there is
no single standard approach to treating relapse after
allo-HSCT; however, there are general principles
that may be considered to guide the treatment of re-
lapse.
Withdrawal of immune suppression and DLI are
routinely considered for patients who relapse after
allo-HSCT and do not have GVHD. With the possi-
ble exception of CML, whether there is a relationship
between cell dose and toxicity with DLI remains un-
clear. Moreover, it is not known whether there is
a dose-response effect, or rather a minimal threshold
dose that must be achieved before antitumor responses
occur. Whether these dose effects might be disease- or
disease state–specific is also unknown. There are clin-
ical situations in which responses to DLI have consis-
tently been poor and maneuvers to improve GVT
induction need to be tested rapidly and comprehen-
sively. The study and elucidation of the mechanisms
underlying relapse should facilitate the development
of disease-specific and patient-specific treatment
strategies.
Given the multitude of confounding issues
and the relatively small numbers of patients, the
Committee on Treatment of Relapse for this
Workshop unanimously acknowledged the need forwell-designed international cooperative trials to rap-
idly test and disseminate the best strategies for treat-
ing relapse after transplantation (Table 7). There is
an absolute need for disease-specific clinical trials,
particularly in situations where cellular therapies
have been ineffective. To facilitate progress in man-
aging disease relapse with cellular, conventional,
and biological therapies, it is recommended that
such clinical trials and the organizations that execute
them contain the following components: (1) creation
and maintenance of databases dealing specifically
with relapse information, (2) measurement of immu-
nologic effects in addition to disease outcomes, (3)
adoption of uniform treatment assessment criteria as
proposed by the Workshop, and (4) design of
relapse-specific Phase I and II studies. It is essential
that pharmaceutical companies and the Food and
Drug Administration (or other international regula-
tory agencies) be actively involved in the design of
such trials. To facilitate the rapid dissemination and
conduct of such trials, it is recommended that an in-
ternational collaborative treatment network dedicated
to the treatment of posttransplantation be estab-
lished. This network would work in collaboration to
bring forward the results of Phase I and II trials for
utilization in Phase III randomized trials within
larger cooperative groups and networks.GENERAL RECOMMENDATIONS
The National Cancer Institute’s First Interna-
tional Workshop on the Biology, Prevention, and
Treatment of Relapse after Allogeneic Hematopoietic
Stem Cell Transplantation closed with an executive
summary session chaired by Dr. Sergio Giralt. This
summary attempted to place the Workshop presenta-
tions into context and to begin to develop overall rec-
ommendations to share with the transplantation
community. Dr. Giralt titled his session ‘‘Where Do
Table 8. General Recommendations from the Organizing
Committee representing the participants in the National
Cancer Institute’s First International Workshop on the Bi-
ology, Prevention, and Treatment of Relapse after Allogeneic
Hematopoietic Stem Cell Transplantation
1. Establishment of multicenter correlative and clinical trials networks:
a. Specific networks of researchers and their specific institutions should
be established in the following areas:
(1) Biology (basic and translational)
(2) Epidemiology
(3) Treatment.
b. Networks may be semiautonomous, but should be collaborative
relative to specific scientific agendas and sample acquisition.
c. To most rapidly implement such networks, investigators and
institutions with specific research interests in relapse and established
core resources should align to address specific research interests.
d. Using specific and prioritized research agendas, all networks should
work in a coordinated and collaborative manner with established
organizations.
2. Establishment of biorepositories for pre‒ and post‒allo-HSCT samples.
a. To aid laboratory and clinical studies of relapse after allo-HSCT, the
following should be collected for deposition within the
biorepositories:
(a) Pretransplantation tumor samples to study resistance
mechanisms
(b) An aliquot from the allograft for assessment of graft composition
(c) Blood samples at set time points posttransplantation and at the
time of relapse for analysis of immune functions
(d) Posttransplantation tumor samples at the time of relapse for
comparison to pretransplantation specimens and for
mechanisms of resistance to both cytotoxic and immunologic
effects of transplantation.
b. Standards need to be established for sample collection, storage, and
administration. It is proposed that investigators and institutions with
established repositories set initial standards and to propose specific
studies.
3. Refinement, acceptance, and implementation of Workshop response and
relapse definitions and monitoring methods
a. Standard methods, criteria, and definitions that are applicable to the
allo-HSCT setting need to be further refined, accepted, and
implemented by all transplantation organizations and incorporated
into clinical trials to:
(1) Determine the clinical relevance of MRD surveillance in
individual diseases;
(2) Assess the potential impact of specific interventional strategies
after detection of MRD.
b. Standard methods, criteria, and definitions are meant to serve as the
major starting point for universal data collection, reporting, and
interpretation in studies related to transplantation after allo-HSCT.
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questions among the participants. This unified query
was based on 2 overarching facts that were reconfirmed
during theWorkshop. First, despite 50 years of animal
studies and 30 years of clinical experience with allo-
HSCT, the questions as to why patients relapse after
allo-HSCT, and what can be done to prevent this
treatment failure, remain completely unanswered. Sec-
ond, outcomes for patients who relapse after allo-
HSCT, with the exception of those in chronic-phase
CML, are not good. The immediate challenge is to es-
tablish research priorities that can rapidly and effi-
ciently result in the greatest scientific and clinical
impact, that will produce results most rapidly and effi-
ciently, and that can be implemented practically and
relatively economically. Most importantly, such prior-
ities need to be relatively well received by the trans-plantation community as a whole. It is with these
parameters in mind that the following general recom-
mendations (Table 8) are made to address the problem
of relapse after allo-HSCT: (1) establishment of mul-
ticenter correlative and clinical trials networks; (2)
establishment of biorepositories for pre– and post–
allo-HSCT samples; and (3) refinement, acceptance,
and implementation of workshop response and relapse
definitions and monitoring methods.Establishment of Multicenter Correlative and
Clinical Trials Networks
To rapidly implement specific studies and trials
dedicated to the treatment of relapse after allo-
HSCT, it is recommended that networks of researchers
and their respective institutions be established in 3 spe-
cific areas: (1) biology of relapse (basic and transla-
tional); (2) epidemiology, defining the risk factors and
predisposing features; and (3) treatment and preven-
tion. These networks could be semiautonomous, but
they need to be collaborative relative to specific scien-
tific agendas and sample acquisition.
Specifically, biology networks, which may be as
few as 2 to several institutions working in collaboration
on specific projects, would work directly with treat-
ment networks to obtain samples collected on treat-
ment protocols. Similarly, epidemiology networks
would receive specific data, whose collection would
be incorporated into treatment protocols. Epidemiol-
ogy networks would comprise institutions willing to
provide extra data that are currently required by the
Center for International Blood and Marrow Trans-
plant Research, the European Group for Blood and
Marrow Transplantation (EBMT), and other interna-
tional transplantation registries. It is imperative that
such epidemiology networks work with, if not directly
through, such agencies to ensure that specific data are
collected at necessary time points to answer important
relapse-specific questions. These would include, but
are not be limited to, data related to monitoring of
MRD, prevention, and treatment. Planning for the
necessary administrative support for the collection of
such data is essential. As such, network participation
would require institutional commitment to collecting
these additional data.
Treatment networks should consist of institutions
that have active clinical research programs dedicated
to the prevention and treatment of relapse. Similar to
the proposed epidemiology networks, treatment net-
works would work directly with or through established
cooperative groups, such as the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN), to
most rapidly and efficiently facilitate clinical protocols.
The keys to the success of this specific recommen-
dation are that (1) all 3 of the proposed research net-
works work in a coordinated and collaborative
452 Biol Blood Marrow Transplant 17:443-454, 2011M. R. Bishop et al.manner with specific and prioritized research agendas
on an international scale; (2) there should be collabo-
ration with or direct use of the resources and infra-
structure of such organizations as the Center for
International Blood andMarrowTransplant Research,
the EBMT, and the Blood and Marrow Transplant
Clinical Trials Network; and (3) there must be ade-
quate funding through specific, directed RFAs,
PO1s, or similar funding mechanisms.Establishment of Biorepositories for Pre– and
Post–Allo-HSCT Samples
The collection of pre– and post–allo-HSCT sam-
ples is needed to aid laboratory and clinical studies of
relapse after allo-HSCT. It was strongly suggested
that the following be collected for deposition within
the biorepositories: (1) pretransplantation tumor sam-
ples when available, to study resistance mechanisms
before the conditioning regimen; (2) an aliquot from
the allograft, for assessment of graft composition and
correlation with relapse; (3) blood samples at set time
points posttransplantation and at the time of relapse,
for analysis of immune functions; and (4) posttrans-
plantation tumor samples at the time of relapse. The
posttransplantation tumor samples would be used for
comparison with pretransplantation specimens and to
probe for mechanisms of resistance to both cytotoxic
and immunologic effects of transplantation.
The availability of such samples would enable the
further study of several of the key issues that have
been identified by specific committees. Relative to
the issue of GVT biology, the ability to prospectively
study various cell populations from multiple patients
under various transplantation conditions would permit
identification of key effector populations, determina-
tion of the effects of various transplantation variables
on cell expansion and contraction, and correlation
of these findings with response to or evasion of GVT
effects. The availability of pretransplantation and post-
transplantation tumor samples provides opportunities
to study the effects of conditioning on epigenetic phe-
nomenon, the clinical significance of CSCs to relapse,
and, possibly most importantly, the relationship of the
resistance to cytotoxic effects and the resistance to
GVT effects.
This effort will require biorepositories for the
collection, storage, and administration of samples.
Standards for sample collection, storage, and adminis-
tration will need to be established. Given the high costs
of the physical infrastructure and for the maintenance,
administration, distribution, and prioritization of sam-
ples in these biorepositories, it is recommended that
investigators and institutions with existing repositories
for transplantation samples convene to set standards
and to propose specific studies, in accordance with
the recommendations of the Workshop Committees.Coordination of efforts among these biorepositories
is essential, and an informatics structure will be critical
to this effort. To support such repositories, we should
promote interactive program grants among institu-
tions to provide synergy, broaden the use of existing
institutional core resources, and build on individual
strengths to study the biology and systematically ad-
dress strategies necessary to overcome posttransplan-
tation relapse. It is also strongly suggested that once
standards are established, sample collection and de-
fined assays at specific time points also should be built
into all clinical transplantation protocols, to facilitate
the translation of basic research into future clinical
research strategies.Refinement, Acceptance, and Implementation
of Workshop Response and Relapse Definitions
and Monitoring Methods
As discussed earlier, standard diagnostic criteria
have been established in the definition of relapse for
many hematologic malignancies. These criteria are
not universally accepted or used, however; definitions
are lacking for certain hematologic malignancies for
which allo-HSCT is used, and many of the available
definitions are not clinically relevant or are insuffi-
cient for use in the allo-HSCT setting. In particular,
the available definitions do not necessarily use more
sensitive methods, such as molecular genetics,
tumor-specific molecular primers, fluorescence in
situ hybridization (FISH), multiparameter flow cy-
tometry, and chimerism, that are commonly used to
monitor patients for relapse after allo-HSCT. One
of the most important questions regarding relapse af-
ter allo-HSCT is the clinical relevance of MRD sur-
veillance in individual diseases, which in turn must be
followed by studies to assess the potential impact of
specific interventional strategies. Such assessment
will be difficult, if not meaningless, if standard
methods, criteria, and definitions that are specifically
applicable to the allo-HSCT setting are not used.
Standard definitions are also important, because sen-
sitivity will increase as techniques improve. It is the
consensus viewpoint of the Workshop that the use
of these proposed methods (Table 5) be accepted
and implemented as the standard by all transplanta-
tion organizations [18,19]. Further refinement of
diagnostic criteria using sensitive methods will be
essential for the success of initiatives and proposed
future studies on the natural history of relapse,
therapeutic interventions to prevent clinical relapse,
and the treatment of relapse. It is well understood
that the proposed methods and definitions have
limitations and are dynamic in that they will require
constant revision as results become available relative
to clinical utility and as new technologies emerge.
Nonetheless, they are meant to serve as the major
Biol Blood Marrow Transplant 17:443-454, 2011 453Summary and Recommendations from NCI Relapse Workshopstarting point for universal data collection, reporting,
and interpretation in studies related to relapse after
allo-HSCT.SUMMARY
It has been more than 50 years since Barnes and
Loutit [32] described the experiments that gave birth
to the field of allo-HSCT, and more than 30 years
since E. Donnall Thomas et al. [33] reported the re-
sults in the first patients with refractory acute leukemia
cured through high-dose therapy and allogeneic bone
marrow transplantation. Although significant ad-
vances have been made in reducing mortality rates
due to toxicity and GVHD, no major advances have
been made in relapse-related mortality. This first
Workshop demonstrated that there exist the scientific
interest and necessary critical mass of investigators to
address the essential biological and mechanistic ques-
tions and to develop trials to study prevention and
treatment of relapse, as well as the need and desire to
work together on such projects. Thus, the provision
of resources and infrastructure to conduct this work
should lead to improved understanding of the causes
underlying relapse after allo-HSCT, as well as to the
development of potential strategies for prevention
and treatment of this complication.ACKNOWLEDGMENTS
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